Palisade Bio, Inc. (Ticker: PALI) has recently exhibited remarkable volatility, which is prominently reflected in the technical charts. On the date in focus, the stock closed at $6.79, witnessing an impressive surge of +37.73% as seen in the first screenshot and +34.89% in the second screenshot. Such a price action invites a multi-dimensional analysis to decipher...
Palisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 -...